APA (7th ed.) Citation

Harbeck, N., Modi, S., Pusztai, L., Ohno, S., Wu, J., Kim, S., . . . Symmans, W. (2026). Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): A randomised, open-label, multicentre, phase III trial. Annals of Oncology, 37(2), 166. https://doi.org/10.1016/j.annonc.2025.10.019

Chicago Style (17th ed.) Citation

Harbeck, N., et al. "Neoadjuvant Trastuzumab Deruxtecan Alone or Followed by Paclitaxel, Trastuzumab, and Pertuzumab for High-risk HER2-positive Early Breast Cancer (DESTINY-Breast11): A Randomised, Open-label, Multicentre, Phase III Trial." Annals of Oncology 37, no. 2 (2026): 166. https://doi.org/10.1016/j.annonc.2025.10.019.

MLA (9th ed.) Citation

Harbeck, N., et al. "Neoadjuvant Trastuzumab Deruxtecan Alone or Followed by Paclitaxel, Trastuzumab, and Pertuzumab for High-risk HER2-positive Early Breast Cancer (DESTINY-Breast11): A Randomised, Open-label, Multicentre, Phase III Trial." Annals of Oncology, vol. 37, no. 2, 2026, p. 166, https://doi.org/10.1016/j.annonc.2025.10.019.